References
- Zimmet PZ, Magliano DJ, Herman WH, et al. Diabetes: a 21st century challenge. Lancet Diabetes Endocrinol. 2014;2:56–64.
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837–853.
- Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117–2128.
- Farmer AJ, Rodgers LR, Lonergan M, et al. MASTERMIND Consortium. Adherence to oral glucose-lowering therapies and associations with 1-Year HbA1c: a retrospective cohort analysis in a large primary care database. Diabetes Care. 2016;39:258–263.
- Kirkman MS, Rowan-Martin MT, Levin R, et al. Determinants of adherence to diabetes medications: findings from a large pharmacy claims database. Diabetes Care. 2015;38:604–609.
- Quilliam BJ, Ozbay AB, Sill BE, et al. The association between adherence to oral anti-diabetic drugs and hypoglycaemia in persons with Type 2 diabetes. Diabet Med. 2013;30:1305–1313.
- Lokhandwala T, Smith N, Sternhufvud C, et al. A retrospective study of persistence, adherence, and health economic outcomes of fixed-dose combination vs loose-dose combination of oral anti-diabetes drugs. J Med Econ. 2016;19:203–212.
- Chong E, Wang H, King-Shier KM, et al. Prescribing patterns and adherence to medication among South-Asian, Chinese and white people with type 2 diabetes mellitus: a population-based cohort study. Diabet Med. 2014;31:1586–1593.
- Peyrot M, Barnett AH, Meneghini LF, et al. Factors associated with injection omission/non-adherence in the global attitudes of patients and physicians in insulin therapy study. Diabetes Obes Metab. 2012;14:1081–1087.
- Yavuz DG, Ozcan S, Deyneli O. Adherence to insulin treatment in insulin-naïve type 2 diabetic patients initiated on different insulin regimens. Patient Prefer Adherence. 2015;9:1225–1231.
- Comparison of medication compliance in diabetes mellitus patients on human versus analogue insulins. Expert Opin Pharmacother. Forthcoming 2016.
- Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007;2:CD005613.
- Sapkota S, Brien JA, Greenfield J, et al. A systematic review of interventions addressing adherence to anti-diabetic medications in patients with type 2 diabetes–impact on adherence. PLoS One. 2015;10:e0118296.
- Parchman ML, Zeber JE, Palmer RF. Participatory decision making, patient activation, medication adherence, and intermediate clinical outcomes in type 2 diabetes: a STARNet study. Ann Fam Med. 2010;8:410–417.
- Egede LE, Gebregziabher M, Dismuke CE, et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35:2533–2539.